AZ876 (AZ 876) is a potent, highly selective LXR agonist with Ki/EC50 of 7/6 nM and 11/73 nM for hLXRα and hLXRβ respectively.
AZ876 is a more potent binder and activator of LXRα and LXRβ than GW3965.
AZ876 is highly selective against FXR, RXR, TRα, TRβ etc.
AZ876 reduces lesion area, and strongly decreases lesion area, lesion number and severity in vivo.
AZ876 protects against pathological cardiac hypertrophy and fibrosis without lipogenic side effects in mice.
